Tianeptine Abuse Leading to an Episode of Psychosis: A Case Report and Literature Review.
Journal
Journal of psychiatric practice
ISSN: 1538-1145
Titre abrégé: J Psychiatr Pract
Pays: United States
ID NLM: 100901141
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
entrez:
6
3
2020
pubmed:
7
3
2020
medline:
8
5
2021
Statut:
ppublish
Résumé
Tianeptine is an atypical mu-opioid receptor agonist. It is available as an antidepressant outside the United States, but it is also classified as a controlled substance in many other countries. It is not approved by the United States Food and Drug Administration for the treatment of depression but it can be obtained online without a prescription. The case described in this article involved a patient who developed symptoms of psychosis on supratherapeutic doses of tianeptine, highlighting the importance of inquiring into all supplements taken by patients when conducting an initial psychiatric evaluation.
Identifiants
pubmed: 32134888
doi: 10.1097/PRA.0000000000000448
pii: 00131746-202003000-00009
doi:
Substances chimiques
Antidepressive Agents, Tricyclic
0
Antipsychotic Agents
0
Receptors, Opioid, mu
0
Thiazepines
0
tianeptine
0T493YFU8O
Paliperidone Palmitate
R8P8USM8FR
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
146-148Références
Samuels BA, Nautiyal KM, Kruegel AC, et al. The behavioral effects of the antidepressant tianeptine require the mu-opioid receptor. Neuropsychopharmacology. 2017;10:2052–2063.
Kasper S, Mcewen BS. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs. 2008;22:15–26.
Novotný V, Faltus F. P.1.132 First signs of improvement with tianeptine in the treatment of depression: an analysis of a double-blind study versus fluoxetine. Eur Neuropsychopharmacol. 2003;13(suppl 4):S230.
Springer J, Cubała WJ. Tianeptine abuse and dependence in psychiatric patients: a review of 18 case reports in the literature. J Psychoactive Drugs. 2018;50:275–280.
Vadachkoria D, Gabunia L, Gambashidze K, et al. Addictive potential of tianeptine: the threatening reality. Georgian Med News. 2009;174:92–94.
Kasper S, Olié JP. A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur Psychiatry. 2002;17 (suppl 3):331–340.
Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.
Wilde MI, Benfield P. Tianeptine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs. 1995;50:156–156.
Atmaca M, Kuloglu M, Tezcan E, et al. Switching to tianeptine in patients with antidepressant-induced sexual dysfunction. Hum Psychopharmacol. 2003;18:277–280.
Bakota EL, Samms WC, Gray TR, et al. Case reports of fatalities involving tianeptine in the United States. J Anal Toxicol. 2018;42:503–509.
Invernizzi R, Pozzi L, Garattini S, et al. Tianeptine increases the extracellular concentrations of dopamine in the nucleus accumbens by a serotonin-independent mechanism. Neuropharmacology. 1992;31:221–227.